Luse Rebecca 4

What Happened

• Rebecca Luse, a director of LB Pharmaceuticals (LBRX), was granted a derivative award on 2026-06-03 covering 10,000 shares. The filing records the acquisition price as $0.00 (award/grant), showing this as a compensation-related derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (timely).
• Transaction type/code: Award/Grant (A); recorded acquisition amount $0.00.
• Shares acquired: 10,000 underlying shares (derivative).
• Shares owned after transaction: Not specified in the supplied filing summary.
• Footnote: 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continuous service through the vesting date.
• No indication of immediate sale or cashless exercise in this filing.

Context

• This was a time‑based equity award (derivative/option) commonly used for director compensation. It does not represent an outright purchase or sale and therefore should not be read as a direct bullish or bearish trade by the insider.
• The award vests only if the director remains in service through the stated vesting date, so its economic benefit to the insider depends on future vesting and any future exercise or sale.